Periprocedural transfusion in patients undergoing transfemoral transcatheter aortic valve implantation.
Nicola Patrick MayrGunther WiesnerAlexander HapfelmeierPieter van der StarreOliver HusserSabine BleizifferHeribert SchunkertRüdiger LangePeter Tassani-PrellKlaus MartinPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
Transfusion was considered necessary in 14% (n = 243) of the patients. Female gender (OR [95% CI]) (1.680 [1.014-2.783]) and preprocedural moderate (7.594 [4.404-13.095]) and severe anemia (8.202 [0.900-74.752]) according to WHO were the most important preprocedural variables. Periprocedural, pericardial effusion (12.109 [3.753-39.063]), emergency extracorporeal circulation (54.5288 [6.178-481.259]) and major vascular injury (2.647 [1.412-4.962]) were related to transfusion. The same applies to moderate (4.255 [1.859-9.740]) and severe anemia (31.567 [8.560-116.416]) as well as periprocedural experience (0.072 [0.035-0.149] - 0.141[0.079-0.251], P < 0.001) CONCLUSION: Procedural experience, serious adverse events, low pre- and periprocedural Hb levels and female gender were the main variables relating to transfusion. Even in experienced high-volume centers, transfusion is still necessary in a considerable number of patients.
Keyphrases
- transcatheter aortic valve implantation
- end stage renal disease
- chronic kidney disease
- cardiac surgery
- percutaneous coronary intervention
- patients undergoing
- direct oral anticoagulants
- sickle cell disease
- aortic valve replacement
- healthcare
- early onset
- public health
- prognostic factors
- aortic valve
- heart failure
- acute kidney injury
- aortic stenosis
- transcatheter aortic valve replacement
- coronary artery disease
- left ventricular